These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11665281)

  • 1. Blood pressure control in diabetic nephropathy.
    Katayama S
    Contrib Nephrol; 2001; (134):113-9. PubMed ID: 11665281
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of nephropathy and lipid disorders. Making progress while heeding Molière's warning.
    Bloomgarden ZT
    Diabetes Care; 1994 Aug; 17(8):946-8. PubMed ID: 7956651
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
    Yokoyama H; Tomonaga O; Hirayama M; Ishii A; Takeda M; Babazono T; Ujihara U; Takahashi C; Omori Y
    Diabetologia; 1997 Apr; 40(4):405-11. PubMed ID: 9112017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient.
    Berecek KH; Farag A; Bahtiyar G; Rothman J; McFarlane SI
    Curr Hypertens Rep; 2004 Jun; 6(3):212-4. PubMed ID: 15128474
    [No Abstract]   [Full Text] [Related]  

  • 6. Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.
    Toto RD
    J Clin Hypertens (Greenwich); 2007 Nov; 9(11 Suppl 4):16-25. PubMed ID: 17978603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to treat the hypertensive diabetic patient.
    Fuller JH
    J Diabetes Complications; 1996; 10(3):144-5. PubMed ID: 8807461
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
    O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
    J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diabetic hypertensive (or hypertensive diabetic)--a compelling need to optimize blood pressure.
    Carruthers SG
    Adv Exp Med Biol; 2001; 498():119-25. PubMed ID: 11900359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic renal disease: from recent studies to improved clinical practice.
    Mogensen CE; Cooper ME
    Diabet Med; 2004 Jan; 21(1):4-17. PubMed ID: 14706048
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of diabetic and hypertensive cardiovascular disease.
    Frohlich ED; Sowers JR
    Curr Hypertens Rep; 2003 Aug; 5(4):309-15. PubMed ID: 12844465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

  • 15. Approach to the treatment of diabetic nephropathy.
    Burke JM
    Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes technology news. Calcium antagonists aid high blood pressure control.
    Walczak IM
    Diabetes Technol Ther; 2003; 5(3):510-1. PubMed ID: 12838935
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy.
    Parving HH
    J Diabetes Complications; 1996; 10(3):133-5. PubMed ID: 8807457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-pressure control preserves renal function.
    Frankel DH
    Lancet; 1998 May; 351(9115):1562. PubMed ID: 10326550
    [No Abstract]   [Full Text] [Related]  

  • 19. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
    Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
    Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypertension and diabetes: mechanisms of elevation of arterial pressure, physiopathologic basis of therapeutic antihypertensives].
    Mogensen CE
    Journ Annu Diabetol Hotel Dieu; 1993; ():161-88. PubMed ID: 8331863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.